Keros Therapeutics Inc. (KROS)
NASDAQ: KROSHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
KROS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $222.26M
- EPS (TTM)
- -$3.22
- Dividend yield
- None
- 52-week range
- 9.69 – 22.55
- Day range
- 10.81 – 11.32
- Volume / Avg
- 195.96K / 197.68K
- Beta
- —
- Shares outstanding
- 19.83M
- Next earnings
- Nov 4, 2026
52-week range
KROS stock today
Shares of Keros Therapeutics (KROS) finished higher on Oct 7 at $11.21, a gain of 1.82% or $0.20 per share, versus the S&P 500's 0.22% decline. Shares are 50.3% below their 52-week high of $22.55, set on Dec 8, 2025 and 15.7% above the 52-week low of $9.69, near the bottom of the past year's range. KROS is down 44.9% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 28.4%.
Keros Therapeutics has posted a net loss over the last twelve months (EPS of -$3.22), so its P/E ratio is not meaningful. Keros Therapeutics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Keros Therapeutics
Company profileKeros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jasbir S. Seehra Ph.D.
- Headquarters
- Lexington, MA
- Employees
- 92
- IPO year
- 2020
- Website
- kerostx.com
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$19.83+76.90%
- Strong buy 0
- Buy 4
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.96
KROS news
All KROS newsKeros Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PLXProtalix BioTherapeutics Inc. (DE) | 2.71 | -0.73% | $218.35M | vs KROS |
| TRDAEntrada Therapeutics Inc. | 5.61 | +3.51% | $218.43M | vs KROS |
| SIONSionna Therapeutics Inc. | 4.82 | +1.47% | $217.62M | vs KROS |
| IVVDInvivyd Inc. | 0.7286 | -9.65% | $214.76M | vs KROS |
| ALECAlector Inc. | 1.92 | +6.08% | $214.38M | vs KROS |
| EVMNEvommune Inc. | 6.22 | -5.90% | $225.74M | vs KROS |
| GLSIGreenwich LifeSciences Inc. | 15.39 | -2.53% | $225.90M | vs KROS |
| MGNXMacroGenics Inc. | 3.55 | -2.47% | $226.14M | vs KROS |
Indexes, lists and sector
Appears in lists
Keros Therapeutics stock FAQ
What is Keros Therapeutics's stock price today?
KROS last traded at $11.21 as of Oct 7, 4:00 PM EDT, up 1.82% on the day. Prices are delayed at least 15 minutes.
When is Keros Therapeutics's next earnings date?
Keros Therapeutics is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.96.
Who is Keros Therapeutics's CEO?
Dr. Jasbir S. Seehra Ph.D. is the chief executive officer of Keros Therapeutics Inc., which has about 92 employees.
What is the KROS 52-week high?
The 52-week high for KROS is $22.55 and the 52-week low is $9.69. The stock is currently 50.3% below its high.